Loxam Teri 4
4 · Vaxcyte, Inc. · Filed Sep 18, 2024
Insider Transaction Report
Form 4
Vaxcyte, Inc.PCVX
Loxam Teri
Director
Transactions
- Sale
Common Stock
2024-09-17$115.32/sh−1,445$166,634→ 11,739 total - Exercise/Conversion
Common Stock
2024-09-17$22.70/sh+6,250$141,875→ 13,425 total - Sale
Common Stock
2024-09-17$114.64/sh−241$27,628→ 13,184 total - Sale
Common Stock
2024-09-17$117.51/sh−256$30,083→ 7,175 total - Exercise/Conversion
Stock Option (right to buy)
2024-09-17−6,250→ 12,500 totalExercise: $22.70Exp: 2032-05-31→ Common Stock (6,250 underlying) - Sale
Common Stock
2024-09-17$116.62/sh−4,308$502,387→ 7,431 total
Footnotes (5)
- [F1]The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on June 18, 2024.
- [F2]The price reported is a weighted-average price. The shares were sold at prices ranging from $113.93 to $114.74. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
- [F3]The price reported is a weighted-average price. The shares were sold at prices ranging from $115.04 to $115.64. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
- [F4]The price reported is a weighted-average price. The shares were sold at prices ranging from $116.25 to $117.04. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
- [F5]Option is fully vested and exercisable.